文献速递淋巴瘤

慢性淋巴细胞白血病中LPL蛋白在突变型与未突变型患者来源不同,为新的预后标志物提供进展

LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL.
PubMed 文献 · Br J Haematol · 2018-06-28

研究评估了表达或不表达LPL mRNA的慢性淋巴细胞白血病(CLL)细胞中LPL蛋白的亚细胞定位。结果显示,突变型CLL的LPL蛋白从细胞外介质摄取,而未突变型患者白血病细胞则从头合成LPL蛋白。内源性LPL蛋白的特异性定量与mRNA表达水平及IGHV突变状态相关,提示LPL蛋白可能作为CLL可靠的预后标志物。

要点

  • 突变型CLL的LPL蛋白来源于细胞外介质摄取。
  • 未突变型患者白血病细胞从头合成LPL蛋白。
  • 内源性LPL蛋白定量与LPL mRNA表达及IGHV突变状态相关。

核心结论

  • LPL蛋白在突变型与未突变型CLL患者中来源不同,内源性LPL蛋白定量与mRNA表达及IGHV突变状态相关,提示LPL蛋白可能作为CLL可靠的预后标志物。

研究设计与样本

  • 评估表达或不表达LPL mRNA的CLL细胞中LPL蛋白的亚细胞定位。

主要发现

  • 突变型CLL的LPL蛋白从细胞外介质摄取,未突变型患者白血病细胞从头合成LPL蛋白。
  • 内源性LPL蛋白的特异性定量与mRNA表达水平及IGHV突变状态相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lipoprotein lipase (LPL) mRNA expression in chronic lymphocytic leukaemia (CLL) is associated with an unmutated immunoglobulin profile and poor clinical outcome. We evaluated the subcellular localization of LPL protein in CLL cells that did or did not express LPL mRNA. Our results show that LPL protein is differently located in CLL cells depending on whether it is incorporated from the extracellular medium in mutated CLL or generated de novo by leukaemic cells of unmutated patients. The specific quantification of endogenous LPL protein correlates with mRNA expression levels and mutational IGHV status, suggesting LPL protein as a possible reliable prognostic marker in CLL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Prieto D, Seija N, Uriepero A, et al. LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL. Br J Haematol. 2018. PMID: 29953583. doi:10.1111/bjh.15427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。